Quanterix Corporation (QTRX)
After hours:
| Previous close | 15.59 |
| Open | 15.80 |
| Bid | 15.52 x 200 |
| Ask | 15.59 x 100 |
| Day's range | 15.52 - 16.01 |
| 52-week range | 11.83 - 29.70 |
| Volume | |
| Avg. volume | 362,635 |
| Market cap | 595.125M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.80 |
Simply Wall St.Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain
Quanterix Corporation ( NASDAQ:QTRX ) shareholders might be concerned after seeing the share price drop 13% in the last...
Business WireQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
BILLERICA, Mass., March 21, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in
ZacksQuanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
